About Panitumumab
            
            Class: | Monoclonal antibody (EGFR inhibitor)  
Use: | Treatment of metastatic colorectal cancer (mCRC) in patients with wild-type KRAS genes, as a single agent or in combination with chemotherapy.  
Adult dose: | 6 mg/kg administered intravenously every 14 days.  
Pediatric dose: | Safety and efficacy in pediatric patients have not been established; not recommended for use in this population.  
Side effects: | Common side effects include skin rash, diarrhea, fatigue, nausea, and infusion-relate
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (EGFR inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of metastatic colorectal cancer (mCRC) in patients with wild-type KRAS genes, as a single agent or in combination with chemotherapy.
                 
                
                
                    
                        Storage Requirements
                    
                    Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Amgen Europe B.V., NETHERLANDS
                    
                    
                    Package Size
                    20ml Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 13872.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        6 mg/kg administered intravenously every 14 days.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy in pediatric patients have not been established; not recommended for use in this population.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include skin rash, diarrhea, fatigue, nausea, and infusion-related reactions.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Known hypersensitivity to panitumumab or any component of the formulation; patients with wild-type KRAS mutations should not receive this therapy.
         
        
        
            
                Important Warnings
            
            Risk of severe skin reactions, infusion-related reactions, and electrolyte imbalances (e.g., hypomagnesemia). Monitor for dermatologic toxicities and electrolyte levels during treatment.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.